Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ALT 
Altimmune Inc (ALT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: ALT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $17.2
1 Year Target Price $17.2
| 5 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.24% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 321.26M USD | Price to earnings Ratio - | 1Y Target Price 17.2 |
Price to earnings Ratio - | 1Y Target Price 17.2 | ||
Volume (30-day avg) 9 | Beta 0.18 | 52 Weeks Range 2.90 - 11.16 | Updated Date 09/14/2025 |
52 Weeks Range 2.90 - 11.16 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -458440% |
Management Effectiveness
Return on Assets (TTM) -32.43% | Return on Equity (TTM) -55.91% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 154000400 | Price to Sales(TTM) 16062.83 |
Enterprise Value 154000400 | Price to Sales(TTM) 16062.83 | ||
Enterprise Value to Revenue 7700.02 | Enterprise Value to EBITDA -4.2 | Shares Outstanding 88257296 | Shares Floating 87577672 |
Shares Outstanding 88257296 | Shares Floating 87577672 | ||
Percent Insiders 0.78 | Percent Institutions 43.32 |
Upturn AI SWOT
Altimmune Inc
Company Overview
History and Background
Altimmune Inc. was founded in 1997. Initially focused on developing intranasal vaccines, the company has evolved to focus on developing treatments for obesity and liver diseases. Significant milestones include progressing multiple drug candidates through clinical trials and securing partnerships and funding.
Core Business Areas
- Obesity: Development of peptide-based therapeutics for obesity, focusing on GLP-1 receptor agonists like pemvidutide.
- Liver Diseases: Development of therapies for non-alcoholic steatohepatitis (NASH) and chronic hepatitis B (CHB).
- Vaccines: While historically focused on vaccines, this area is now less emphasized than obesity and liver diseases.
Leadership and Structure
Dr. Vipin K. Garg is the President and CEO. The company has a typical biotech organizational structure, with research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Pemvidutide: A GLP-1 receptor agonist under development for obesity. It is currently in Phase 2 clinical trials. Market share is currently zero as it is not yet commercialized. Competitors include Novo Nordisk (NVO) with Wegovy and Ozempic, and Eli Lilly (LLY) with Mounjaro and Zepbound. Revenue is currently zero, focusing on future potential.
- HepTcell: An immunotherapeutic being developed for chronic hepatitis B (CHB). It is in Phase 1/2 clinical trials. Market share is zero as it is not commercialized. Competitors include Gilead Sciences (GILD) and Vir Biotechnology (VIR). Revenue is currently zero, focusing on future potential.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and regulatory hurdles. The obesity and NASH markets are experiencing significant growth due to increasing prevalence of these conditions and limited treatment options.
Positioning
Altimmune is a clinical-stage biopharmaceutical company. Its competitive advantage lies in its innovative peptide-based therapeutics and its focus on unmet medical needs in obesity and liver diseases. However, it faces competition from larger, more established pharmaceutical companies.
Total Addressable Market (TAM)
The obesity market is estimated to reach hundreds of billions of dollars. The NASH market is expected to be equally large. Altimmune is positioning itself to capture a portion of these large markets with its pipeline of drug candidates.
Upturn SWOT Analysis
Strengths
- Innovative drug development platform
- Strong clinical pipeline
- Experienced management team
- Focus on high-growth markets
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Competition from larger companies
- No currently approved products
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Regulatory approvals
- Expansion into new indications
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from new therapies
- Economic downturn
Competitors and Market Share
Key Competitors
- NVO
- LLY
- GILD
- VIR
Competitive Landscape
Altimmune faces intense competition from large pharmaceutical companies with established products and significant resources. Altimmune's advantages include its innovative technology and focus on unmet medical needs. The main disadvantage is its limited resources and lack of commercialized products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by pipeline advancement and financing. No sales have occurred, and it is a pre-revenue company.
Future Projections: Future growth hinges on the success of pemvidutide and HepTcell. Analyst estimates vary widely, but positive clinical trial data could lead to significant stock price appreciation.
Recent Initiatives: Recent initiatives include enrolling patients in clinical trials for pemvidutide and HepTcell, as well as exploring potential partnerships.
Summary
Altimmune is a clinical-stage biotech company with promising drug candidates in the high-growth obesity and liver disease markets. Its success hinges on positive clinical trial results and securing partnerships. The company faces significant competition and financial risks but also has the potential for substantial stock price appreciation if its products are approved.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings (10-K, 10-Q), Company website, Analyst reports, ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotech industry is highly volatile, and investments in companies like Altimmune carry significant risk. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Altimmune Inc
Exchange NASDAQ | Headquaters Gaithersburg, MD, United States | ||
IPO Launch date 2005-10-06 | President, CEO & Director Dr. Vipin K. Garg Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website https://altimmune.com |
Full time employees 59 | Website https://altimmune.com | ||
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.